Pharmacogenomic Effect/ADR for Tramadol (DBSNPE006631)
- Identifier
- DBSNPE006631
- Drug
- Tramadol (DB00193)
- Interacting Gene/Enzyme
- Cytochrome P450 2D6
- Gene Name
- CYP2D6
- UniProt ID
- P10635
- Defining Change(s)
-1770G>A Not Available -1584C>G Not Available -1235A>G Not Available -740C>T Not Available -678G>A Not Available CYP2D7 gene conversion in intron 1 Not Available 310G>T Not Available 746C>G Not Available 843T>G Not Available 1661G>C Not Available 2850C>T Not Available 3384A>C Not Available 3584G>A Not Available 3790C>T Not Available 4042G>A Not Available 4180G>C Not Available 4481G>A Not Available - Allele Name
- CYP2D6*31
- Genotype(s)
- Not Available
- Type(s)
- ADR Inferred Effect
- Groups
- Non-functional CYP2D6
- Description
- Poor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.
- References
- Ultram® (tramadol hydrochloride) tablets[package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; 2016. [Link]